Current and future challenges in the development of antimicrobial agents

Handbook of Experimental Pharmacology

Volumn 211, Issue , 2012, Pages 45-65

  Rennie, Robert P ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Animal models; Antimicrobial resistance; Drug development; Stewardship

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AMPHOTERICIN B; ANTIINFECTIVE AGENT; CARBAPENEM; CARBAPENEMASE; CEFDINIR; CEFIXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; FLUCONAZOLE; FLUCYTOSINE; IMIPENEM; ITRACONAZOLE; LINCOSAMIDE DERIVATIVE; MACROLIDE; PENICILLIN G; PIPERACILLIN; POSACONAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TOBRAMYCIN; UNINDEXED DRUG; UREIDOPENICILLIN DERIVATIVE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BIOLOGICAL MODEL; CLOSTRIDIUM DIFFICILE; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; ESCHERICHIA COLI; GENE SEQUENCE; GENETIC VARIABILITY; GONORRHEA; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HAEMOPHILUS INFLUENZAE TYPE A; HUMAN; HYPOKALEMIA; KIDNEY DYSFUNCTION; LIVER TOXICITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; MYCOSIS; NEISSERIA GONORRHOEAE; NONHUMAN; PENICILLIN RESISTANCE; PHARMACODYNAMICS; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; TUBERCULOSIS; VANA GENE; VANB GENE; VANC GENE; VANCOMYCIN RESISTANT ENTEROCOCCUS; VAND GENE; VANE GENE; VANF GENE; ANIMAL; ANIMAL MODEL; ANTIFUNGAL RESISTANCE; DRUG DEVELOPMENT; DRUG EFFECT; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; REVIEW;

ANIMALS; ANTI-INFECTIVE AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, FUNGAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MODELS, ANIMAL;

EID: 84870213153     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-28951-4_4     Document Type: Article

References (58)

1. Ananda-Rajah MR, Slavin MA, Thursky KT (2012) The case for antifungal stewardship. Curr Opin Infect Dis 25:107-115
2. Andes D, Craig WA (2002) Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 19:261-268 (Pubitemid 34308974)
3. Andes D, van Ogtrop ML, Peng J, Craig WA (2002) In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 46:3484-3489 (Pubitemid 35192915)
4. Aperis G, Alivanis P (2011) Posaconazole: a new antifungal weapon. Rev Recent Clin Trials 6:204-219
5. Bast D, Yue M, Chen X, Bell D, Dresser L, Saskin R, Mandell LA, Low DE, de Azavedo JCS (2004) Novel murine model of pneumococcal pneumonia: use of temperature as a measure of disease severity to compare the efficacies of moxifloxacin and levofloxacin. Antimicrob Agents Chemother 48:3343-3348 (Pubitemid 39129329)
6. Bolan GA, Sparling PF, Wasserheit JN (2012) The emerging threat of untreatable gonococcal infection. N Engl J Med 366:485-487
7. Bowyer P, Moore CB, Rautemaa R, Denning DW, Richardson MD (2011) Azole antifungal resistance today: focus on Aspergillus. Curr Infect Dis Rep 13:485-491
8. Boyd N, Nailor MD (2011) Combination antibiotic therapy for empiric and definitive treatment of gram-negative infections: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 31:1073-1084
9. Bryskier A (2005) Epidemiology of resistance to antimicrobial agents. In: Bryskier A (ed) Antimicrobial agents: antibacterials and antifungals. ASM, Washington, DC, pp 39-92
10. Bush K, Jacoby GA, Medeiros AA (1995) A functional classification scheme for beta - A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 39:1211-1233
11. Bush K (2008) Extended-spectrum beta-lactamases in North America, 1987-2006. Clin Microbiol Infect 14(Suppl 1):134-143 (Pubitemid 350284182)
12. Bush K, Jacoby GA (2010) Updated functional classification of beta-lactamases. Antimicrob Agents Chemother 2010(54):969-976
13. Chambers HF (2001) The changing epidemiology of Staphylococcus aureus. Emerg Infect Dis 7:178-182
14. Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-10
15. Craig WA (2001) Does the dose matter? Clin Infect Dis 15(Suppl 3):S233-S237 (Pubitemid 32835797)
16. Davies J (2006) Where have all the antibiotics gone? Can J Infect Dis Med Microbiol 17:287-290 (Pubitemid 44898667)
17. D'Costa VM, King CE, Kalan L, Morar M, Sung WW, Schwarz C, Froese D, Zazula G, Calmels F, Debruyne R, Golding GB, Poinar HN, Wright GD (2011) Antibiotic resistance is ancient. Nature 477:457-461
18. den Braber I, Mugwagwa T, Vrisekoop N, Westera L, Müogling R, Bregje de Boer A, Willems N, Schrijver EH, Spierenburg G, Gaiser K, Mul E, Otto SA, Ruiter AF, Ackermans MT, Miedema F, Borghans JA, de Boer RJ, Tesselaar K (2012) Maintenance of peripheral naive T cells is sustained by thymus output in mice but not humans. Immunity 36:288-297
19. Deurenberg RH, Vink C, Kalenic S, Friedricjh AW, Bruggeman CA, Stobbeeringh EE (2007) The molecular evolution of methicillin-resistant Staphylococus aureus. Clin Microbiol Infect 13:222-235 (Pubitemid 46603352)
20. Diazgranados CA (2011) Prospective audit for antimicrobial stewardship in intensive care: Impact on resistance and clinical outcomes. Am J Infect Control. 2011 Sep 20. Epub ahead of print. In press
21. Fabrino DL, Leon LL, Genestra M, Parreira GG, Melo RC (2011) Rat models to investigate host macrophage defense against Trypanosoma cruzi. J Innate Immun 3:71-82
22. Farrell DJ, Jenkins SG, Brown SD, Patel M, Lavin BS, Klugman KP (2005) Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance. Emerg Infect Dis 11:851-858 (Pubitemid 40720845)
23. Farrell DJ, Morrissey I, Bakker S, Morris L, Buckridge S, Felmingham D (2004) Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B)- and mef(A)-mediated macrolide resistance. J Clin Microbiol 42:764-768 (Pubitemid 38222659)
24. Gardner P, Smith DH, Beer H, Moellering RC (1969) Recovery of resistance (R) factors from a drug-free community. Lancet 294:774-776
25. Ison CA, Alexander S (2011) Antimicrobial resistance in Neisseria gonorrhoeae in the UK: surveillance and management. Expert Rev Anti Infect Ther 9:867-876
26. Jenkins SG, Farrell DJ (2009) Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis 15:1260-1264
27. Jiang Z, Vasil AI, Hale JD, Hancock RE, Vasil ML, Hodges RS (2008) Effects of net charge and the number of positively charged residues on the biological activity of amphipathic alpha-helical cationic antimicrobial peptides. Biopolymers 90:369-383
28. Jiang Z, Vasil AI, Gera L, Vasil ML, Hodges RS (2011) Rational design of a-helical antimicrobial peptides to target Gram-negative pathogens, Acinetobacter baumannii and Pseudomonas aeruginosa: utilization of charge, 'specificity determinants', total hydrophobicity, hydrophobe type and location as design parameters to improve the therapeutic ratio. Chem Biol Drug Des 77:225-240
29. Jones RN, Fritsche TR, Sader HS, Ross JE (2006) Activity of retapamulin (SB-275833), a novel peuromutilin, against selected resistant gram-positive cocci. Antimicrob Agents Chemother 50:2583-22586
30. Karlowsky J, Zhanel G, Hammond G, Rubinstein E, Wylie J, Du T, Mulvey M, Alfa M (2012) Multidrug-resistant, NAP2 Clostridium difficile was the predominant toxigenic, hospital-acquired strain in the Province of Manitoba, Canada in 2006-2007. J Med Microbiol 61(3): 693-700
31. Katz AR, Komeya AY, Soge OO, Kiaha MI, Lee MV, Wasserman GM, Maningas EV, Whelen AC, Kirkcaldy RD, Shapiro SJ, Bolan GA, Holmes KK (2012) Neisseria gonorrhoeae with high-level resistance to azithromycin: case report of the first isolate identified in the United States. Clin Infect Dis 54:841-843
32. Laudano JB (2011) Ceftaroline fosamil: a new broad-spectrum cephalosporin. J Antimicrob Chemother 66(Suppl 3):11-18
33. López-Rojas R, Sánchez-Céspedes J, Docobo-Pérez F, Domínguez-Herrera J, Vila J, Pachón J (2011) Pre-clinical studies of a new quinolone (UB-8902) against Acinetobacter baumannii resistant to ciprofloxacin. Int J Antimicrob Agents 38:355-359
34. Maurya IK, Pathak S, Sharma M, Sanwal H, Chaudhary P, Tupe S, Deshpande M, Chauhan VS, Prasad R (2011) Antifungal activity of novel synthetic peptides by accumulation of reactive oxygen species (ROS) and disruption of cell wall against Candida albicans. Peptides 32 (8):1732-1740
35. Mulcahy H, Sibley CD, Surette MG, Lewenza S (2011) Drosophila melanogaster as an animal model for the study of Pseudomonas aeruginosa biofilm infections in vivo. PLoS Pathog 7:e1002299
36. Parr TR Jr, Bayer AS (1988) Mechanisms of aminoglycoside resistance in variants of Pseudomonas aeruginosa isolated during treatment of experimental endocarditis in rabbits. J Infect Dis 158:1003-1010 (Pubitemid 18266050)
37. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP (2008) Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 29:1099-2106
38. Pfaller MA (2012) Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 125(Suppl):S3-13
39. Pitman SK, Drew RH, Perfect JR (2011) Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations. Expert Opin Emerg Drugs. Aug 17 Epub ahead of print
40. Richmond MH (1976) The presence of a variant of type-IIIa beta-lactamase in a series of strains isolated in a burns unit. J Med Microbiol 9:363-364
41. Rodríguez-Baño J, Navarro MD, Romero L, Muniain MA, de Cueto M, Ríos MJ, Hernández JR, Pascual A (2006) Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 431:407-414
42. Rodríguez-Baño J, Miró E, Villar M, Coelho A, Gozalo M, Borrell N, Bou G, Conejo MC, Pomar V, Aracil B, Larrosa N, Agüuero J, Oliver A, Fernández A, Oteo J, Pascual A, Navarro F (2012) Colonisation and infection due to Enterobacteriaceae producing plasmid-mediated AmpC β-lactamases. J Infect 64:176-183
43. Sader HS, Jones RN (2007) Cefdinir: an oral cephalosporin for the treatment of respiratory tract infections and skin and skin structure infections. Expert Rev Anti Infect Ther 5:29-43
44. Schwartz-Cornil I, Bonneau M, Dalod M, Bertho N (2011) Impact of large mammals models in immunology. Reprod Fertil Dev 24:287-288
45. Spanakis EK, Aperis G, Mylonakis E (2006) New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 43:1060-1068 (Pubitemid 44631109)
46. Subramanian S, Roberts CL, Hart CA, Martin HM, Edwards SW, Rhodes JM, Campbell BJ (2008) Replication of colonic Crohn's disease mucosal Escherichia coli isolates within macrophages and their susceptibility to antibiotics. Antimicrob Agents Chemother 52:427-434 (Pubitemid 351170809)
47. Sutcliffe JA (2011) Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci 1241:122-152
48. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG (2006) Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the Infectious Diseases Society of America. Clin Infect Dis 42:657-668 (Pubitemid 43271379)
49. Talbot GH (2008) What is the pipeline for Gram-negative pathogens? Expert Rev Anti Infect Ther 6:39-49
50. Tsai TY, Chang SC, Hsueh PR, Feng NH, Wang JT (2007) In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections. J Microbiol Immunol Infect 40:481-486
51. Unemo M, Shafer WM (2011) Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future. Ann N Y Acad Sci 1230:E19-28
52. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P (2012) High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: Novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 56:1273-1280
53. Venugopal AA, Johnson S (2012) Fidaxomicin: a novel marcocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin Infect Dis 54:568-574
54. Wasan KM, Sivak O, Rosland M, Risovic V, Bartlett K (2007) Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and Am Bisome in combination with caspofungin to rats infected with Aspergillus fumigatus. J Pharm Sci 96:1737-1747 (Pubitemid 47122952)
55. Weiss K (2006) Vancomycin-resistant enterococci: the value of infection control and antibiotic control policy. Can J infect Dis Med Microbiol 17(Suppl):9B-12B
56. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR (2009) Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 53:5046-5054
57. Zellweger JP (2011) Multidrug resistant tuberculosis - its extent, hazard and possible solutions. Rev Mal Respir 28:1025-1033
58. Zhanel GG, Lam A, Schweizer F, Thomson K, Wlakty A, Rubinstein E, Gin AS, Hoban DJ, Noreddin AM, Karlowsky JA (2008) Ceftribiprole: a review of a braod-spectrum and anti-MRSA cephalosporin. Am J Clin Dermatol 9:245-264